Goals of this presentation:
1.Prevent morbidity and mortality due to the failure to recognize Primary Immunodeficiency
2. Decrease your risk of having to answer the question: “Why did you miss this?”
3. Review the safe and effective use of gamma globulin
Presentation by:
Richard L. Wasserman, M.D.,Ph.D.
Clinical Professor of Pediatrics
University of Texas Southwestern Medical School
Goals of this presentation:
1.Prevent morbidity and mortality due to the failure to recognize Primary Immunodeficiency
2. Decrease your risk of having to answer the question: “Why did you miss this?”
3. Review the safe and effective use of gamma globulin
Presentation by:
Richard L. Wasserman, M.D.,Ph.D.
Clinical Professor of Pediatrics
University of Texas Southwestern Medical School
This presentation is an overview of primary and secondary immunodeficiency disorders with highlights on the genetic basis of primary disorders and associated factors underlying secondary disorders, as well a management of these disorders
Pediatric Home Service Medical Director, Dr. Roy Maynard discusses deficiencies of innate immune system and other well-defined immunodeficiency syndromes.
This presentation is an overview of primary and secondary immunodeficiency disorders with highlights on the genetic basis of primary disorders and associated factors underlying secondary disorders, as well a management of these disorders
Pediatric Home Service Medical Director, Dr. Roy Maynard discusses deficiencies of innate immune system and other well-defined immunodeficiency syndromes.
Learning Objectives
Define the recurrent infections and differentiate the patient with a primary immunodeficiency (PID) from the "normal person“.
Recognize infectious signs and symptoms, and opportunistic infections of primary immunodeficiency that warrant screening and referral to a specialist.
Understand noninfectious signs and symptoms that should raise concern for primary immunodeficiency.
Determine appropriate testing for patients for whom immunodeficiency is suspected.
Discuss the management of patients with primary immunodeficiency.
Appreciate secondary causes of immunodeficiency
This presentation is about chronic infections in patients and earlier diagnosis of immunodeficiency. The goals of the presentation are:
1. Understand the role of innate and adaptive immune systems in the defense against infection
2. Recognize the common presentations of common primary immunodeficiencies
3. Be able to identify patients in an ENT practice that may have a primary immunodeficiency
Presentation by: Dr. Richard L. Wasserman and Dr. Scott Manning
Antibiotic resistance occurs when bacteria change in response to the use of these medicines. A growing number of infections – such as pneumonia, tuberculosis, gonorrhoea, and salmonellosis – are becoming harder to treat as the antibiotics used to treat them become less effective. Antibiotic resistance leads to longer hospital stays,higher medical costs and increased mortality.
Controversy: the role of immunomodulator in allergic caseSuharti Wairagya
dipresentasikan oleh Erwanto BW Teguh HK
Divisi Alergi Imunologi Klinik Departemen 1. Penyakit Dalam FKUI/RSCM Bagian Penyakit Dalam SMF non Bedah RS. dr. H. Marzoeki Mahdi Bogor
An article on contamination of Diethylene Glycol in Pharmaceuticals. Thanks to Dr. Ajaz S. Hussain for all teaching, sharing knowledge and supporting in professional development.
Specific ServPoints should be tailored for restaurants in all food service segments. Your ServPoints should be the centerpiece of brand delivery training (guest service) and align with your brand position and marketing initiatives, especially in high-labor-cost conditions.
408-784-7371
Foodservice Consulting + Design
Senior Project and Engineering Leader Jim Smith.pdfJim Smith
I am a Project and Engineering Leader with extensive experience as a Business Operations Leader, Technical Project Manager, Engineering Manager and Operations Experience for Domestic and International companies such as Electrolux, Carrier, and Deutz. I have developed new products using Stage Gate development/MS Project/JIRA, for the pro-duction of Medical Equipment, Large Commercial Refrigeration Systems, Appliances, HVAC, and Diesel engines.
My experience includes:
Managed customized engineered refrigeration system projects with high voltage power panels from quote to ship, coordinating actions between electrical engineering, mechanical design and application engineering, purchasing, production, test, quality assurance and field installation. Managed projects $25k to $1M per project; 4-8 per month. (Hussmann refrigeration)
Successfully developed the $15-20M yearly corporate capital strategy for manufacturing, with the Executive Team and key stakeholders. Created project scope and specifications, business case, ROI, managed project plans with key personnel for nine consumer product manufacturing and distribution sites; to support the company’s strategic sales plan.
Over 15 years of experience managing and developing cost improvement projects with key Stakeholders, site Manufacturing Engineers, Mechanical Engineers, Maintenance, and facility support personnel to optimize pro-duction operations, safety, EHS, and new product development. (BioLab, Deutz, Caire)
Experience working as a Technical Manager developing new products with chemical engineers and packaging engineers to enhance and reduce the cost of retail products. I have led the activities of multiple engineering groups with diverse backgrounds.
Great experience managing the product development of products which utilize complex electrical controls, high voltage power panels, product testing, and commissioning.
Created project scope, business case, ROI for multiple capital projects to support electrotechnical assembly and CPG goods. Identified project cost, risk, success criteria, and performed equipment qualifications. (Carrier, Electrolux, Biolab, Price, Hussmann)
Created detailed projects plans using MS Project, Gant charts in excel, and updated new product development in Jira for stakeholders and project team members including critical path.
Great knowledge of ISO9001, NFPA, OSHA regulations.
User level knowledge of MRP/SAP, MS Project, Powerpoint, Visio, Mastercontrol, JIRA, Power BI and Tableau.
I appreciate your consideration, and look forward to discussing this role with you, and how I can lead your company’s growth and profitability. I can be contacted via LinkedIn via phone or E Mail.
Jim Smith
678-993-7195
jimsmith30024@gmail.com
The Team Member and Guest Experience - Lead and Take Care of your restaurant team. They are the people closest to and delivering Hospitality to your paying Guests!
Make the call, and we can assist you.
408-784-7371
Foodservice Consulting + Design
Artificial intelligence (AI) offers new opportunities to radically reinvent the way we do business. This study explores how CEOs and top decision makers around the world are responding to the transformative potential of AI.
The case study discusses the potential of drone delivery and the challenges that need to be addressed before it becomes widespread.
Key takeaways:
Drone delivery is in its early stages: Amazon's trial in the UK demonstrates the potential for faster deliveries, but it's still limited by regulations and technology.
Regulations are a major hurdle: Safety concerns around drone collisions with airplanes and people have led to restrictions on flight height and location.
Other challenges exist: Who will use drone delivery the most? Is it cost-effective compared to traditional delivery trucks?
Discussion questions:
Managerial challenges: Integrating drones requires planning for new infrastructure, training staff, and navigating regulations. There are also marketing and recruitment considerations specific to this technology.
External forces vary by country: Regulations, consumer acceptance, and infrastructure all differ between countries.
Demographics matter: Younger generations might be more receptive to drone delivery, while older populations might have concerns.
Stakeholders for Amazon: Customers, regulators, aviation authorities, and competitors are all stakeholders. Regulators likely hold the greatest influence as they determine the feasibility of drone delivery.
2. OR
Centre for Quality Sciences ET-WAP
Empirical Therapeutics in War Against Pandemic
Live talk on 17 June 2020, Wednesday in Urdu
10.30 to 11 PM followed by Q & A
What we know, What we don’t know
& How do we know
9. Small Proteins … Cell Signaling
Includes Chemokines, Interferons,
Interleukins, Lymphokines, Tumor
Necrosis Factor
Produced by B & T lymphocyte
Mast cells, Endothelial cells, Fibroblasts,
Macrophages, Stromal cells
Cytokine
11. • Bone macrophogenetic protein to treat
bone related conditions
• Erythropoietin to treat anemia
• Granulocyte Colony Stimulating Factor
(GCSF) to treat neutropenia
• Granulocyte Macrophage Colony
Stimulating Factor (GmCSF) to treat
neutropenia & fungal infections in
cancer patientsCytokine Usage
12. • Interferon alpha used to treat Heaptitis
C & Multiple Sclerosis
• Interferon Gamma used to treat chronic
Granulomotus disease & Osteopetrosis
• Interferon beta used to treat Multiple
Sclerosis
Cytokine Usage
13. • Interleukin 2 used to treat cancer
• Interleukin 11 used to treat
thrombocytopenia in cancer patients
Cytokine Usage
17. 1997 – TCZ developed
2005 – Approved in Japan
2009 – Approved in EMA
2010 – Approved in US-FDA
IL-6 discovered in
Japan – 1980s
18. China used for 21 patients in March
Australia recommended for off-
label use
Italy used for few cases
Randomized studies started
CoVid - 19
19. For 330 patients around the world
… under trial
End point assessing clinical status,
mortality, mechanical ventilation &
ICU Variables in the patient
population
Trial COVACTA
21. Bind with
Soluble & Membrane bound
receptors
69% of 45 patients with life threatening
cytokine release syndrome resolved within
14 days of one or two doses
IL-6
Receptor Antagonist
22. Life threatening matter &
no treatment option
Infections, TB, Immune disorders
Benefit Risk Assessment
23. Serious infections leading to death
Tuberculosis, Bacterial, invasive
fungal, viral & opportunistic
infections
Latent TB test is mandatory
Warning
24. • Patients with chronic or recurrent
infections
• Who have been exposed to TB
• With a history of serious or
opportunistic infections
• Who have resided or traveled in an area
of endemic TB or mycosis
• With underline conditions that may
predispose them to infectionsWeigh the Risk for
25. • Herpes zoster exacerbation observed in
clinical studies
• Uncertainty prevails for hepatitis
patients
Viral Reactivation
27. • Highly uncertain due to immunological
cross-response
• Dangerous for use of live vaccine
Vaccination
28. B cell chronic lymphocytic
leukemia & RA
Over secretion of Cytokine triggers a
dangerous cytokine storm
6 patients in Phase 1 Trial
London, Parexell , 2006
500 times lower dose safe in animals
Systemic Organ Failure
TGN-1412 – Theralizumab